Technical Reports on Biotech Equities -- Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ

Tuesday, June 13, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 13, 2017 /PRNewswire/ --

DailyStockTracker.com has issued research reports on Amgen Inc. (NASDAQ:

AMGN), Pulmatrix Inc. (NASDAQ: PULM), Argos Therapeutics Inc. (NASDAQ: ARGS), and Bioverativ Inc. (NASDAQ: BIVV). According to an article on Seeking Alpha, the high-beta Biotech sector has been subdued since it opened the year with a solid January. The
dearth of M&A activity since then has been a primary contributor to the very narrow range this part of the markets have been gyrating within throughout most of 2017. Earnings have been solid from the industry, but not spectacular. Learn more about these stocks by downloading their comprehensive and free reports from DailyStockTracker.com member's area at:

http://dailystocktracker.com/register/

Amgen 

On Monday, shares in Thousand Oaks, California headquartered Amgen Inc. rose 0.50%, ending the day at $164.88. The stock recorded a trading volume of 4.34 million shares, which was above its three months average volume of 3.71 million shares. The Company's shares have advanced 3.00% in the last one month and 12.77% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 2.51% and 2.68%, respectively. Moreover, shares of Amgen, which discovers, develops, manufactures, and delivers human therapeutics worldwide, have a Relative Strength Index (RSI) of 66.22.

On June 08th, 2017, Amgen announced that it will present at the Goldman Sachs 38th Annual Global Healthcare Conference on June 13th, 2017, at 2:40 p.m. PT in Rancho Palos Verdes, Calif. Sean E. Harper, M.D., executive vice president of Research and Development, will present at the conference. The live audio of the presentation can be accessed under Investors section of the Company's website. AMGN complete research report is just a click away and free at:

http://dailystocktracker.com/registration/?symbol=AMGN

Pulmatrix 

Shares in Lexington, Massachusetts headquartered Pulmatrix Inc. ended the day 4.18% lower at $2.52 with a total trading volume of 182,697 shares. The stock has surged 327.12% on an YTD basis. The Company's shares are trading above their 200-day moving average by 18.96%. Furthermore, shares of Pulmatrix, which engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology, have an RSI of 40.55. The complimentary report on PULM can be downloaded at:

http://dailystocktracker.com/registration/?symbol=PULM

Argos Therapeutics 

At the close of trading on Monday, shares in Durham, North Carolina headquartered Argos Therapeutics Inc. finished 1.05% lower at $0.40 with a total trading volume of 121,759 shares. The stock is trading below its 50-day moving average by 7.04%. Shares of the Company, which focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases, have an RSI of 47.32. Sign up for your complimentary research report on ARGS at:

http://dailystocktracker.com/registration/?symbol=ARGS

Bioverativ 

Waltham, Massachusetts headquartered Bioverativ Inc.'s shares recorded a trading volume of 1.05 million shares at the end of yesterday's session. The stock closed the day 3.05% lower at $55.24. The Company's shares have advanced 0.36% in the past month, 5.99% in the previous three months, and 16.29% on an YTD basis. The stock is trading above its 200-day moving average by 6.75%. Additionally, shares of Bioverativ, which focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the US and Japan, have an RSI of 46.45.

On May 23rd, 2017, Bioverativ announced that it has entered into a definitive agreement to acquire South San Francisco-based True North Therapeutics, a privately held, clinical-stage, rare disease biotechnology company, for an upfront payment of $400 million plus assumed cash. True North investors are also eligible to receive additional payments of up to $425 million contingent on the achievement of future development, regulatory and sales milestones.

On May 24th, 2017, research firm Credit Suisse upgraded the Company's stock rating from 'Underperform' to 'Neutral'. Get free access to your research report on BIVV at:

http://dailystocktracker.com/registration/?symbol=BIVV

 

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook